RR15. Multilayer Flow Modulator Stents (MFM) as a Therapeutic Option in the Management of Thoraco-abdominal Aortic Aneurysms  by Sultan, Sherif et al.
Independent predictors (P .01) were type II TAAA (OR
2.7, 95%CI 1.8-3.9) and aneurysm rupture (OR 2.52;
95%CI 1.00-6.33; P .04). Patient survival at 3-years was
significantly decreased in patients with SCI compared to
those who did not have this complication (66% vs 31%, P
01).
Conclusions: SCI occurs in 14% of patients treated for
TAAAs with ADSG and is associated with extent of aortic
disease and aneurysm rupture. Patients with SCI have
higher morbidity rates and decreased long-term survival.
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RR15.
Multilayer Flow Modulator Stents (MFM) as a Therapeu-
tic Option in the Management of Thoraco-abdominal
Aortic Aneurysms
Sherif Sultan1, NiamhHynes2, Wael Tawfick1. 1Vascular &
Endovascular Surgery, Western Vascular Institute, Galway,
Ireland; 2Galway Clinic, Galway, Ireland
Objectives: Patients with Thoraco-abdominal Aortic
Aneurysm have been classically managed by open surgical
repair since 1955 but despite advances in surgical technique
and the introduction of less invasive endovascular tech-
niques, morbidity and mortality rates remain high. We
report outcome using a novel uni-modular multi-layer
stent technology.
Methods: Out of 172 cases implanted worldwide we
present the first 26 cases, in 7 countries, that were fully
analyzed through the MFM registry. All were Crawford
Thoraco-abdominal aortic aneurysms (11 Type II, 9 Type
III, and 6 Type IV); 75% were male; median age was
73years (57-91); 79.7% were ASA IV E; 62 % were reinter-
vention after previous TEVAR; mean aneurysm diameter
was 67mm and mean length was 167mm.
Results: All stents were deployed to their intended
target. No Aneurysm-related death occurred within 18
Months. No peri-operative Visceral or Renal insult oc-
curred. There were no Cerebrovascular accidents, paraple-
gia or loss of visceral branches patency during follow up. At
6 months, mean sac volume shrunk by 8% with lumen
volume reduction of 14%. Average thrombus volume in-
creased but thrombus to lumen ratio decreased by 23%.
Finite Element Analysis post MFM documented dampen-
ing of wall displacement by 80%. Wall pressure fell to 200
Pa with immediate depressurization of the aortic sac and
dissipation of the maximum pressure zone. There was 55%
immediate reduction in Wall Stress.
Conclusions:MFMcarries no risk of critical shuttering
or loss of native side branches. With physiological modula-
tion of the aneurysm, Volume Sac reduction was docu-
mented in 65% of cases. MFM offers immense promise for
resolution of complex Thoraco-abdominal aneurysms.
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Branched-Fenestrated and Chimney-type Endovascu-
lar Repairs for Juxtarenal and Thoracoabdominal Aor-
tic Aneurysms
Mark Fillinger. Dartmouth Hitchcock Medical Center,
Lebanon, NH
Objectives: To report outcomes for branched-fenes-
trated (BEVAR) and chimney-type endovascular repair
(CEVAR) of juxtarenal (JAAA) and thoracoabdominal aor-
tic aneurysms (TAAA) as part of review for a multicenter
IDE study and CMS LCD coverage.
Methods: From 11/05 to 11/11, patients with
JAAA and TAAA who were a prohibitive risk for open
repair but at high risk of rupture were treated with
complex endovascular interventions at a single institu-
tion. Review included CEVAR and surgeon-modified
BEVAR cases with at least 1 month follow-up. Hybrid
aortic debranching cases were excluded from this IRB-
approved review.
Results: Out of 107 repairs (85 BEVAR, 22 CEVAR),
repair extent was 64 TAAA (15 Type II, 24 Type III, 25
Type IV) and 43 JAAA. TAAA were treated with BEVAR
(63/64), while JAAA were treated with both (21 CEVAR,
22 BEVAR). Repair was urgent in 15, with 3 ruptured.
Mortality (30-day plus Hospital) was 4.7% (TAAA 4/64,
6% and JAAA 1/43, 2%). Paraplegia/paresis not resolving
with therapy occurred in 2 (Type II and III extent TAAAs).
Aortic endografts were successfully implanted in all cases.
Of the 273 target branches for stent-graft implantation
(245 BEVAR, 28 CEVAR), 269 were successful, with 2
performed in delayed fashion. All 269 were patent at dis-
charge. No patients required dialysis. One patient had
sigmoid colon ischemia after coverage of a patent IMA.
Beyond 30 days, all branches remained patent. A single
Type I endoleak (1 CEVAR) and 3 Type III endoleaks (3
BEVAR) were resolved with percutaneous intervention.
Other secondary interventions were performed for branch
stenosis (2), compartment syndrome (1) and adjacent aor-
tic degeneration (1). There were no other Type I/III
endoleaks, migration, aneurysm expansion, or rupture.
Conclusions: With appropriate anatomy, early results
of BEVAR and CEVAR for JAAA and TAAA can be good,
even in patients at a prohibitive risk for open repair. At this
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